Upper respiratory tract infections have minimal impact on neffy’s pharmacokinetics or pharmacodynamics
John Oppenheimer, Thomas B. Casale, Carlos A. Camargo, David M. Fleischer, David I. Bernstein, Richard Lowenthal, Sarina Tanimoto
Abstract
Epinephrine is the first-line treatment for severe allergic reactions, and epinephrine autoinjectors are the most common method of administration. However, despite injectable epinephrine’s history of safety and efficacy, patients and caregivers are reluctant to administer injections. Most report delaying or failing to administer epinephrine during an allergic reaction,1 resulting in an increased risk of complications and hospitalizations.2
Topics & Concepts
MedicinePharmacodynamicsPharmacokineticsRespiratory tract infectionsRespiratory tractCoronavirus disease 2019 (COVID-19)Intensive care medicinePharmacologyRespiratory systemInternal medicineInfectious disease (medical specialty)DiseaseRespiratory and Cough-Related ResearchPoisoning and overdose treatmentsAsthma and respiratory diseases